IP Verse

Edaravone Suspension For Oral Administration

Patent No. EP3875085 (titled "Edaravone Suspension For Oral Administration") was filed by Mitsubishi Tanabe Pharma on Nov 1, 2019. The application was issued on Jun 19, 2024.

Patent Summary

Edaravone suspension for oral administration that achieves therapeutic efficacy comparable to intravenous injections while reducing the burden on patients and caregivers. The suspension contains edaravone particles dispersed in a water-based solution with added stabilizers and pH regulators. The formulation enables sustained release of edaravone through the gastrointestinal tract, with a dosing regimen of 90-120 mg per oral administration.

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
MAIWALDMar 19, 2025MAIWALD

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3875085

MITSUBISHI TANABE PHARMA
Application Number
EP19880770A
Filing Date
Nov 1, 2019
Status
Granted And Under Opposition
May 17, 2024
Publication Date
Jun 19, 2024
External Links
Slate, Register , Google Patents